Company intelligence / Profile preview

1849 bio

San Francisco, California, United States1849.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

1849 bio has developed a synthetic biology platform to engineer microbes that enable efficient, low-cost extraction of metals such as copper and nickel from low-grade ores. Their approach aims to unlock stranded metal resources that are currently uneconomical to mine using conventional methods. The company is at an early stage with no reported commercial deployments yet.

Modalities: Microbial engineeringSynthetic biology
Industry: Non-Drug Biotech

Partnerships

Y Combinator accelerator program/investment

Beyond the preview

Go deeper on 1849 bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1849 bio.

Explore the full profile